Gilde Healthcare closes oversubscribed €250 million ($285 million) later stage and growth capital fund - Gilde Healthcare

Gilde Healthcare closes oversubscribed €250 million ($285 million) later stage and growth capital fund

June 14, 2016

New fund targets innovative scale-up opportunities in medtech, digital health and therapeutics

Utrecht, The Netherlands and Cambridge, Massachusetts – Gilde Healthcare, the European specialist investment firm, today announces the final close of Gilde Healthcare IV, a €250 million ($285 million) later stage and growth capital fund. The new fund, which was oversubscribed, is targeting investments in innovative private scale-up opportunities in medtech, digital health and therapeutics both in Europe and North America.

Gilde Healthcare IV, which closed at its hard cap, is backed by a balanced mix of international investors. Royal Philips (NYSE: PHG, AEX: PHIA) acted as a cornerstone investor, extending the collaboration which started in the previous Gilde Healthcare III fund. Johnson & Johnson Innovation – JJDC, Inc. joined as a new corporate investor in Gilde Healthcare IV. Additional investors include fund-of-funds, sovereign funds such as Danish Growth Fund, endowments, family offices, entrepreneurs and Gilde partners. The European Investment Fund participated in the fund through several of its funding programs including the European Recovery Program and Dutch Venture Initiative II.

Investors have been attracted by Gilde Healthcare’s strong track record. In the last three years, Gilde exited 14 portfolio companies across its healthcare funds realizing significant value for its investors. Amongst the companies that were successfully divested over this period are Definiens, the leading provider of image analysis software for digital pathology; Inovalabs, which markets portable oxygen concentrators for patients with respiratory conditions; ProFibrix, which developed a novel topical hemostatic agent to treat fast bleeding wounds; Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design; Santaris, which develops RNA-targeted drugs and Sapiens, a Dutch neuro-modulation company focused on deep brain stimulation for patients suffering from Parkinson’s disease.

Pieter van der Meer, Managing Partner of Gilde Healthcare commenting on today’s release said,

“The healthcare landscape in the US and Europe is changing, driven by the need for more patient centric care and a much sharper focus on value. With our new fund we will continue to pursue our differentiated investment strategy of backing growth and later stage companies developing novel technologies or therapeutics that enable better healthcare outcomes at reduced costs.”

Gilde Healthcare’s hands-on investment team, which is based on both sides of the Atlantic, actively supports the international growth of its companies. The Gilde Healthcare IV Fund will make equity investments in a single portfolio company of between €15-25 million.

 

About Gilde Healthcare

Gilde Healthcare is based in Utrecht, The Netherlands and Cambridge, Massachusetts. The firm is organized along two business lines managing separate funds for innovative healthcare technology companies and lower mid-market healthcare services companies.

Gilde has raised over €800 million ($910 million) in dedicated healthcare funds and is actively looking to lead new private investments in medtech, digital health, therapeutics and healthcare services.

For a list of Gilde Healthcare’s portfolio companies please visit the website at www.gildehealthcare.com.

Media Contact
Pieter van der Meer
Managing Partner

Gilde Healthcare
Tel: +31.30.219.2533
https://gildehealthcare.com

Gilde Healthcare portfolio company Nyxoah announces CE-mark approval to treat complete concentric collapse (CCC) patients

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved...
October 5, 2021

Gilde Healthcare portfolio company Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors. Dr. Jonas is a neuropsychiatry expert...
October 4, 2021

Gilde Healthcare company Acacia Pharma announces marketing authorization application for BARHEMSYS® in Europe

Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces...
September 29, 2021